**Prognostic value of EIF5A2 in solid tumors: a meta-analysis**

Jianwen Fang 1, Xiaocong Jiang 1, Xi Shang 2, Haixing Shen 3,4, Yuexin Lu 1, Yue Lu 5, Jingyan Zheng 6 and Peifen Fu 1, \*

1 Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

2 Department of Breast and Thyroid Surgery, Taizhou Hospital, Zhejiang University, Taizhou, Zhejiang 318000, China

3 Zhejiang University School of Medicine, Hangzhou 310003, China

4 Department of Breast and Thyroid Surgery, Cixi People's Hospital, Cixi, Zhejiang 315300, China

5 Department of Breast and Thyroid Surgery, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China

6 Department of Breast and Thyroid Surgery, Lishui People's Hospital, The Six Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, China

\* Correspondence: Peifen Fu; e-mail address: fupeifen@zju.edu.cn; fax number: 0086-571-87236706

**Aims:** The mechanism of cancer metastasis is still not well understood. Therefore, there is an urgent need to elucidate the underlying mechanisms of cancer metastasis and to find effective biomarkers to benefit cancer treatment. EIF5A2 may be a useful prognostic marker in cancer.

****Method:**Relevant studies were identified by a comprehensive search of the PubMed, EMBASE and Web of Science databases. Hazard ratios (HRs) and odds ratios with 95% CIs were applied to explore the association between EIF5A2 and survival outcome and clinical characteristics.**

**Results:** The pooled analysis showed that high EIF5A2 expression was significantly associated with worse overall survival and disease-free survival/progression-free survival/relapsefree survival.

**Conclusions:** EIF5A2 is an effective prognostic marker in solid tumors. In this work, we pooled the existing evidence for meta-analysis to assess the prognostic value of EIF5A2 in solid tumors, and evaluated the reliability of EIF5A2 as a prognostic indicator.